In this study, we want to see what happens when one of the drugs in a 4-drug combination called Dara-RVd is given once a week instead of twice a week. We will look at how this timing change affects the outcome of multiple myeloma with autologous stem cell transplantation. This is a hybrid decentralized study where some if not all assessments may be performed close to your home.

We know multiple myeloma can take a long time to diagnose. In this study, we want to better understand how your myeloma was diagnosed so we can identify ways to improve the process.

Have you been diagnosed with cancer. If so, you may be able to take part in a research study looking to improve cancer care for patients whose treatment outcomes have led to challenges in their quality of life.

Have you been diagnosed with Multiple Myeloma? Have you received idecabtagene vicleucel (ide-cel (Abecma)) CAR-T treatment? If so, you may be able to take part in a research study looking at for how long a new drug called iberdomide will keep Multiple Myeloma under control (in remission).

Are you dealing with multiple myeloma that keeps coming back or hasn't improved? If you are, you may be able to join a study to see if a new drug called ABBV-383 could be safe and helpful for people in your situation. You will be reimbursed for travel expenses. You will not have to pay for the drug while you take part in this study.

Are you interested in improving your physical health and wellbeing during or after cancer treatment? If so, our free 12- week exercise program might be a good fit for you! We are creating a registry of adults with a cancer diagnosis who have gone through our program.

Have you been diagnosed with relapsed or refractory multiple myeloma? If so you may be able to take part in a research study looking at the safety and efficacy of giving BMS-986393 to patients with multiple myeloma.

The survey and its findings will help us understand attitudes around cancer family history and genetic testing among Black people. This information will be used to develop an educational curriculum to strive towards health equity for Black people diagnosed with or at higher risk of cancer and get Black people the best cancer care.

The purpose of this research study is to learn more about the risk of severe and fatal infusion-related reactions (IRR) in patients with multiple myeloma who are treated with their first 3 administrations of daratumumab. Examples of severe IRR include lung tightness, low oxygen levels, difficulty breathing, high blood pressure, racing heart, headache, and too much fluid in the lungs. No fatal IRRs have been observed in clinical trials of daratumumab. We are also doing this study to help us to identify potential risk factors for IRR.

Do you have multiple myeloma with MGRS-associated kidney disease? If so, you may be able to take part in a research study looking at the safety and effectiveness of a combination of medications for patients with multiple myeloma with MGRS-associated kidney disease.